Artery Network has exclusively learned that Amed Medical Devices (Beijing) Co., Ltd. (“Améd Medical” or “Amed”) has recently completed a Series D financing round of over RMB 200 million. The round was led by Zhesheng Collaborative Life Health Fund, with participation from Henan Key Intellectual Property Fund, Global Hedge Fund Management Co., Ltd., and other institutions. Following this financing, Améd Medical’s post-investment valuation exceeds RMB 1.5 billion.

According to the company, the proceeds will mainly be used for the R&D and global registration of its core series of 3D-printed biodegradable vascular stents, as well as market promotion of its newly launched China-first CO₂ contrast injection device. Rising Demand for Vascular Interventions and the “Implant-Free Intervention” Trend Drive Rapid Growth of Biodegradable Stents and Interventional Auxiliary Devices
Driven by population aging and other factors, the number of patients with cardiovascular diseases has grown rapidly. In China alone, the 2024 Report on Cardiovascular Health and Diseases in China issued by the National Center for Cardiovascular Diseases shows that as many as 330 million people are living with cardiovascular diseases nationwide, including 13 million stroke patients, 11.39 million coronary heart disease patients, 45.3 million peripheral artery disease patients, and 245 million hypertension patients. Meanwhile, the China Health Statistics Yearbook 2024 indicates that cardiovascular diseases remain the leading cause of death among both urban and rural residents in China.
The rapid development of minimally invasive interventions and improved patient disease awareness have boosted demand for pan-vascular interventional diagnosis and treatment, fueling strong growth in the market for related medical devices.
With advances in medicine, the concept of “implant-free intervention” has gained increasing clinical acceptance. In coronary interventions, for example, implant-free products such as drug-coated balloons and biodegradable stents can dilate stenotic vessels without leaving permanent implants, offering patients superior treatment options. Furthermore, biodegradable stents in the coronary intervention market have not yet been included in centralized procurement, leaving broad room for growth for innovative enterprises.

Against this backdrop, Améd Medical has targeted the pan-vascular intervention field — covering cardiovascular, peripheral vascular, and neurovascular segments — and built a rich pipeline of biodegradable stents and interventional supporting products. To date, the company has obtained 5 medical device registration certificates, including multiple balloon dilatation catheters, a China-first stent locator for precise positioning during stenting for aorto-coronary ostial lesions, and a pioneering CO₂ contrast injection device.

Key advanced pipeline products include:
• A second-generation fully absorbable sirolimus-eluting coronary stent (3D-printed PLLA material, cardiovascular intervention)
• A fully absorbable paclitaxel-eluting superficial femoral artery stent (3D-printed PLCL material, peripheral vascular intervention)
Both have entered the special review process for innovative medical devices and are in clinical trials or registration applications. In neurovascular intervention, Améd Medical is developing China’s only pipeline biodegradable intracranial stent.

Of particular note is Jetfall® CO₂ Contrast Pressure Injection Kit, a Class III innovative medical device recently approved in China as the first of its kind.

Currently, iodine-based contrast agents are widely used in clinical angiography, but they are contraindicated in patients with iodine allergies, renal insufficiency, or thyroid diseases, leaving some patients ineligible for interventional surgery. The CO₂ contrast injection device enables clear imaging via DSA, as carbon dioxide is exhaled through the lungs after circulation, with no air embolism risk, no residue in the body, no renal or hepatic toxicity, and no allergenicity.

Améd Medical has already signed partnerships with distributors nationwide, securing prepayments in the tens of millions of yuan. The launch of Jetfall® is expected to trigger a wave of technological product replacement in the domestic contrast media market.

As a product admitted to the NMPA’s Innovative Medical Device Review Pathway, Jetfall® received strong support from the Center for Medical Device Evaluation (CMDE) and the Beijing Municipal Medical Products Administration. Dedicated specialists provided one-on-one guidance throughout the application process, allowing the device to obtain its registration certificate in just 9 months from acceptance. This efficient review fully reflects regulators’ strong encouragement and substantive support for domestically innovated medical devices.

In global markets, Améd Medical obtained EU CE-MDR certification and US FDA clearance before receiving NMPA approval, and has secured registrations in the UK, Brazil, Turkey, and other regions, with overseas sales launched in September last year.

Beyond pan-vascular interventions, Améd Medical has also developed non-vascular implantable products, including biodegradable biliary stents and medical-grade biodegradable poly(L-lactide-co-ε-caprolactone) (PLCL) polymers. The company recognizes the growth potential of biliary stents and aims to expand its product portfolio using proprietary biodegradable polymers.

Supported by 3D Multi-Axial Precision Manufacturing Platform, Améd Builds Comprehensive Core Patent Portfolio in R&D and Manufacturing

As China’s only enterprise with both fully biodegradable coronary and peripheral stents in clinical trials, and the only domestic company capable of one-step processing from raw resin pellets to finished biodegradable stents, Améd Medical relies on its core 3D Multi-Axial Printing (3D-MAP) technology platform.

In materials, Améd was selected in 2023 as a lead unit under the Ministry of Industry and Information Technology and NMPA’s “Top-Notch R&D Program for Biomedical Materials” (First Batch) to develop PLCL and other advanced materials. Its upstream material layout is expected to enable domestic substitution of medical biodegradable polymers, supporting the R&D of high-end domestic medical devices.

PLCL, a novel biodegradable medical polymer synthesized via block copolymerization of PLA and PCL monomers, achieves molecular-level balance between rigidity and flexibility. It features excellent biocompatibility, biodegradability, high strength, and elasticity, with promising applications in ligament, bone, and vascular tissue engineering. By mastering proprietary biodegradable medical polymers, Améd aims to reduce reliance on imported materials, achieve independent and controllable production, and significantly lower manufacturing costs.
Technologically, the 3D-MAP platform enables one-step forming of biodegradable stents. Most global manufacturers traditionally use laser cutting (subtractive manufacturing), which involves multi-step processing, low material utilization, low efficiency, low yield, and high costs. Moreover, extensive patents in this field are held by overseas companies, restricting domestic development.

Améd’s 3D-MAP additive manufacturing platform resolves longstanding challenges of 3D-printed vascular stents. It greatly improves material utilization, produces structures unachievable by laser cutting, streamlines production via one-step forming, and boosts efficiency. It also reduces material trial-and-error costs and development time. By avoiding overseas patent clusters in laser cutting, Améd has captured high ground in medical 3D printing innovation. The company holds dozens of invention patents in China, the US, and Europe covering 3D printing methods, structural design, and production equipment.

Biodegradable stents produced via 3D-MAP have achieved complete endothelialization within two weeks in animal studies. In terms of degradation rate, coronary stents fully degrade in approximately three years on average, while peripheral stents degrade in about two and a half years. In over 200 clinical cases of coronary stenting, the maximum follow-up period has reached six years with zero incidence of thrombosis.

Behind Améd’s innovative 3D-MAP platform is a highly cohesive, experienced R&D team with cross-disciplinary expertise. Several core members have over 30 years of experience in biomaterials and device development, including veterans from Medtronic, Abbott, and other top device manufacturers who led R&D and clinical research of biodegradable vascular stents. More than 40% of the R&D team has overseas study experience, and nearly 50% hold doctoral degrees.

Industry Outlook and Investor & Management Comments

Amid the implant-free intervention trend, biodegradable stents have emerged as a key industry focus, with numerous players developing solutions including biodegradable metal stents and polymer-based biodegradable stents. Améd Medical believes the biodegradable stent market is large enough to support diverse technical exploration toward more optimal and feasible solutions. Future development will center on maximizing material advantages. The company is willing to collaborate with clinicians and industry peers to develop better solutions for patients and physicians.

Mr. Luo Yu, Investment Director of Zhesheng Collaborative Life Health Fund, stated:“We are honored to lead this round of financing in Améd Medical. As a healthcare-focused investment institution, our backing reflects strong confidence in both its underlying technological innovation and global execution capabilities. The company’s flagship CO₂ contrast device has achieved outstanding initial sales overseas, validating its robust technological barriers and mature global commercialization capacity. This marks Chinese medical devices’ transition from ‘scale catch-up’ to ‘value definition’ and ‘global rule-setting.’

We are particularly optimistic about Améd’s ‘diagnosis + treatment’ full-stack platform strategy in vascular interventions built on this success. Its series of 3D-printed biodegradable stents are at critical stages of clinical trials or registration applications, representing industrial evolution from ‘disease treatment’ to ‘full-cycle health management.’ By deeply integrating high-end imaging diagnosis and innovative implant therapy, the platform creates strong clinical synergy and ecological competitiveness.
We believe this financing will accelerate the formation of its strategic closed loop, helping Améd become a global leader in vascular interventions, delivering more China-originated solutions to global patients, and leading the industry from ‘domestic substitution’ to ‘global value creation.’”

Dr. Liu Qing, Founder of Améd Medical, commented:“This financing marks Améd Medical’s official transition from a ‘technology pioneer’ to an ‘industry leader.’ Going forward, we will focus on two core fronts:First, seize the policy window for innovative medical devices in China to rapidly expand access to whole peripheral solutions centered on fully absorbable peripheral stents and CO₂ contrast products, enabling domestic patients to benefit from world-leading domestic innovative devices.Second, continue to build academic and technological leadership by deepening cooperation with top clinical centers such as Beijing Anzhen Hospital Affiliated to Capital Medical University, Chinese PLA General Hospital (301 Hospital), and Zhongshan Hospital Affiliated to Fudan University, establishing clinical training bases for CO₂ contrast techniques, and promoting the standardization and internationalization of vascular disease diagnosis and treatment in China.”

Dr. Zhao Qinghong, Chief Scientist of Améd Medical, added:“This financing is the best recognition of Améd’s 15 years of dedicated innovation and a call to launch an all-out offensive into cutting-edge international research. Funds will be firmly invested in original technology R&D: accelerating clinical evidence accumulation for peripheral biodegradable stents, continuously optimizing CO₂ contrast products to bring non-nephrotoxic contrast to more high-risk patients, and accelerating global commercial layout to write a new chapter in the overseas expansion of ‘China Smart Manufacturing.’

Competition in medical devices ultimately comes down to core technologies. Améd will uphold long-termism, address the most intractable clinical challenges through frontier innovation, and aspire to become the most trusted ‘source of technological innovation’ in pan-vascular care in China and worldwide.”